Loading
Obesity / Overweight / Tirzepatide · Phase 2 Trial
ClinicalTrials.gov · August 11, 2026
Early or partial results. Treat as a signal, not a conclusion.
This is a Phase 2 trial registration (not yet reporting results) examining RO7204239 combined with tirzepatide versus placebo plus tirzepatide for weight loss in adults with obesity or overweight and comorbidities. The study is actively enrolling and will assess body weight change at 48 weeks as the primary endpoint. No efficacy, safety, or pharmacokinetic data are available from this registry record.
Phase 2, Interventional, Randomized, Parallel, Quadruple masking, Treatment purpose. Obesity, Overweight, Overweight With One Weight Related Comorbidity; age from 18 Years. Intervention: RO7204239 low dose + Tirzepatide; RO7204239 medium dose + Tirzepatide; RO7204239 high dose + Tirzepatide. Compared with: Placebo + Tirzepatide — Active Comparator. n = 285. 35 sites across 4 countries.
This is a Phase 2 trial registration (not yet reporting results) examining RO7204239 combined with tirzepatide versus placebo plus tirzepatide for weight loss in adults with obesity or overweight and comorbidities. The study is actively enrolling and will assess body weight change at 48 weeks as the primary endpoint. No efficacy, safety, or pharmacokinetic data are available from this registry record.
This is a registry record; no efficacy, safety, pharmacokinetic, or pharmacodynamic results are reported.
This trial is not yet mature; clinicians should monitor for results as they become available. The combination of RO7204239 with tirzepatide is investigational, and no clinical recommendation can be made until efficacy and safety data are published.
This is a Phase 2 interventional trial registration with planned enrollment of 285 participants; no results are reported in this registry record, making it an early-stage, ongoing study.
As stated by the source record.
Quoted from the source exactly as published.
This trial is not yet mature; clinicians should monitor for results as they become available. The combination of RO7204239 with tirzepatide is investigational, and no clinical recommendation can be made until efficacy and safety data are published.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
What is missing. This record has no key findings. That is a gap in the analysis, not a judgement about the study.
Registry record from ClinicalTrials.gov (NCT06965413). This is a study registration, not published results. Lead sponsor: Hoffmann-La Roche. Recruitment status: ACTIVE_NOT_RECRUITING. Phase: PHASE2. Study type: INTERVENTIONAL. Enrollment: 285 participants (ACTUAL). Conditions: Obesity, Overweight, Overweight With One Weight Related Comorbidity. Interventions: DRUG: RO7204239; DRUG: RO7204239 Matching Placebo; DRUG: Tirzepatide. Primary outcome measures: Percent Change From Baseline in Body Weight , Baseline, Week 48. Brief summary: The main aim of the study is to assess the effect of RO7204239 in combination with tirzepatide, compared to placebo in combination with tirzepatide, on body weight loss after 48 weeks of treatment in adults with obesity or overweight with at least one weight-related comorbidity, but without diabetes mellitus (DM). The study comprises of a 4-week screening period; a 48-week core treatment period, where all participants will receive tirzepatide as background treatment and will be randomized to one of the 4 treatment arms; a 24-week treatment extension period, where participants will stop treatment with tirzepatide and a 24-week post-treatment follow-up (FU) period.
Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.